These humanized monoclonal antibodies target inhibitory receptors (CTLA-4, PD-1, LAG-3, TIM-3) or ligands (PD-L1) expressed on T lymphocytes, antigen presenting cells, and tumor cells and elicit an anti-tumor response by stimulating the immune system. This evidence concerns the gene LAG3 and neoplasm.